MedTrace Logo

The Analgesic Efficacy of Ultrasound Guided Transversus Abdominal Plane Block After Abdominal Cancer Surgeries

NCT03165383 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-05-24

No results posted yet for this study

Summary

Effective postoperative pain control results in decreased cardiac and pulmonary complications, patient satisfaction and early mobilization. A prospective, randomized comparative study was done of analgesic efficacy, opioid requirement and side effects in patients undergoing lower abdominal cancer surgeries. In Study Group Ultrasound guided Transversus Abdominis Plane (TAP) block was given and control Group no TAP block was given. Patient controlled analgesia (PCA) with intravenous morphine was given to both group patients, and total good PCA demands in both the groups was studied.

Conditions

  • Abdominal Cancer

Interventions

DRUG

Bupivacaine (Transversus Abdominis Plane Block)

Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly up to 24 hours.

DRUG

Intravenous Patient Controlled Analgesia (PCA) Morphine

PCA Intravenous Morphine 1 milligram bolus on demand was given as rescue analgesia up to 24 hours.

Sponsors & Collaborators

  • Rajiv Gandhi Cancer Institute & Research Center, India

    lead OTHER

Principal Investigators

  • Anita Kulkarni, MD · Rajiv Gandhi Cancer Institute and Research Centre , Delhi , India 110085

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-11
Primary Completion
2014-07-10
Completion
2014-08-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03165383 on ClinicalTrials.gov